Loading organizations...
§ Private Profile · Seattle, WA, USA
pharmaceutical development company developing novel antibiotic formulations for resistant infections, focused on infectious disease.
Cardeas Pharma is a Seattle, Washington-based pharmaceutical development company that creates novel antibiotic formulations specifically designed to address highly resistant bacterial infections. The organization focuses on advancing specialized therapeutics within the infectious disease sector to provide new clinical treatment options for complex pathogens. The executive leadership and corporate board bring extensive commercial experience from prominent biotechnology enterprises and venture capital firms, including Gilead, Corus, Curalogic, and Novo Ventures. Operating as an independent entity for over a decade, the enterprise guided its proprietary antibiotic pipeline through various stages of pharmaceutical development before being officially acquired in May 2024. The strategic direction of the firm was managed by a core executive team that included Chief Operating Officer Melissa Yeager. Cardeas Pharma was originally founded in 2013 by former Gilead senior vice president Dr. Alan Bruce Montgomery.
Cardeas Pharma has raised $34.0M across 1 funding round.
Cardeas Pharma has raised $34.0M in total across 1 funding round.
Cardeas Pharma has raised $34.0M across 1 funding round. Most recently, it raised $34.0M Series B in May 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 23, 2013 | $34M Series B | Aaron Davidson | Avalon Ventures, Delphi Ventures, Devon Park Bioventures, Novo Holdings, WRF Capital | Announced |
Cardeas Pharma has raised $34.0M in total across 1 funding round.
Cardeas Pharma's investors include Aaron Davidson, Avalon Ventures, Delphi Ventures, Devon Park Bioventures, Novo Holdings, WRF Capital.